Sweeteners and Sweetness Enhancers: Prolonged Effects on Health, Obesity and Safety
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 379
- 试验地点
- 7
- 主要终点
- Change in body weight (adults)
研究概览
简要总结
The aim of this randomised controlled trial (RCT) is to investigate if prolonged consumption of sweetener and sweetness enhancers (S&SEs) within a healthy diet approach will improve weight loss maintenance and obesity related risk factors, and affect safety markers, compared to sugar.
We hypothesize, that:
- Prolonged use of S&SEs in beverages and food matrices will result in improved body weight control because S&SEs will increase palatability of the diet and thereby increase compliance to the recommendations for a healthy diet.
- There will be no safety concerns using S&SEs in the long term.
Overweight/obese adults and families where at least one adult (both gender) and one child (both gender) are overweight/obese will be recruited. The majority of measurements will only be conducted in the adult population and some measurement will only be done in sub-groups. The intervention will be performed in four countries: Denmark, Greece, Spain and the Netherlands.
The goal is approximately 370 participants - 330 adults (18-65 years of age) and 40 children (6-12 years of age) - will be recruited for the study. All adult participants are first treated by a low energy diet (LED) for 2 months with the aim to reduce body weight (minimum 5% weight loss (WL)), whereas children are treated separately with a conventional weight maintenance (WM) diet, without a specific aim for absolute WL.
The participants - both adults and families - are randomized into two different diet interventions for 10 months with or without inclusion of S&SEs products (foods and drinks). For adults, this period aims at preventing weight re-gain and for children maintaining body mass index (BMI)-for-age. The participants will receive food exchange lists and will be guided by dieticians. The randomization will be stratified by age, sex and BMI. Adults (not participating with children) belonging to the same household and all members of a family will be assigned the same intervention - the randomization will here solely be based on the oldest adult in the family/household.
The adult participants are weighed at months 0, 0.5 and 1, and if needed at month 1.5. They are supervised during the WL period at months 0 and 1, and if needed at months 0.5 and 1.5, and throughout the WM period at months 2, 4, 6, 9 and 12. Children will follow a similar, but less strict time schedule (their participation is preferred but not required for all dietician meetings).
The main assessment points are the clinical investigation days (CIDs) at month 0 (baseline, start of the WL period), 2 (end of the WL period/start of randomized intervention), 6 (6 months from baseline) and 12 (1 year from baseline).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 65 Years(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Change in body weight (adults)
时间窗: Up to 1 year.
Efficacy: Change in body weight will be measured by a calibrated digital scale.
Changes in gut microbiota composition (adults)
时间窗: Up to 1 year.
Safety: Change in gut microbiota associated with impaired health (e.g. change in microbial beta-diversity and composition) will be measured by fecal samples.
次要结局
- Change in BMI-for-age z-score (children)(Up to 1 year.)
- Changes in waist and hip circumferences (adults and children)(Up to 1 year.)
- Change in blood pressure and heart rate (adults and children)(Up to 1 year.)
- Change in body composition (adults and children)(Up to 1 year.)
- Change in hemoglobin A1c (adults and children)(Up to 1 year.)
- Change in alanine aminotransferase (ALT) (adults and children)(Up to 1 year.)
- Change in insulinemia (adults and children)(Up to 1 year.)
- Change in glucose (adults and children)(Up to 1 year.)
- Adverse events (adults and children)(Up to 1 year.)
- Change in aspartate aminotransferase (AST) (adults and children)(Up to 1 year.)
- Change in lipidemia (adults and children)(Up to 1 year.)
- Allergenicity by a skin prick test (adults)(Up to 1 year.)
- Allergenicity by a questionnaire (adults and children)(Up to 1 year.)
- Concomitant medication (adults and children)(Up to 1 year.)
- Change C-reactive protein (CPR) (adults and children)(Up to 1 year.)
- Change in liver fat and lipid composition (adults)(Up to 1 year.)
- Change in FGF21 (adults)(Up to 1 year.)
- Allergenicity by serum immunoglobulin level (adults and children)(Up to 1 year.)
- Change in ghrelin (adults)(Up to 1 year.)
- Changes in gut microbiota composition (children)(Up to 1 year.)
- Change in cholecystokinin (adults)(Up to 1 year.)
- Change in glucagon-like peptide-1 (GLP-1) (adults)(Up to 1 year.)
- Markers of adipogenesis (adults)(Up to 1 year.)
- Fat cell size (adults)(Up to 1 year.)
- Changes in gut-microbial composition in response to specific S&SEs in vitro (adults)(Only baseline feces samples will be used)
- Inflammation markers (adults)(Up to 1 year.)
- Glucose tolerance (adults)(Up to 1 year.)
- Lipolysis (adults)(Up to 1 year.)
- Baseline and postprandial energy expenditure (adults)(Up to 6 months.)
- Insulin sensitivity (adults)(Up to 1 year.)
- Baseline and postprandial appetite (adults)(Up to 6 months.)
- Baseline and postprandial blood samples (adults)(Up to 6 months.)
- Baseline and postprandial substrate oxidation (adults)(Up to 6 months.)
- Changes in gut-microbial functionality in response to S&SEs in vitro (adults)(Up to 1 year.)
研究者
Anne Birgitte Raben
Professor
University of Copenhagen
